Evidence map›Paper›PMID 37608893›Full record

ArticleFrontiers in pharmacology2023

Design, synthesis and antitumour activity evaluation of novel dolutegravir derivatives.

Xi-Xi Hou, Long-Fei Mao, Yajie Guo, Chaoxuan Lou, Lan Wang, Rui-Fang Li, Huili Wang, San-Qiang Li, Jian-Xue Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xi-Xi HouDepartment of Pharmacy, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
Long-Fei MaoCollege of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, China.
Yajie GuoDepartment of Emergency, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
Chaoxuan LouDepartment of Pharmacy, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
Lan WangCollege of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, China.
Rui-Fang LiCollege of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, China.
Huili WangUniversity of North Carolina Hospitals, Chapel Hill, NC, United States.
San-Qiang LiCollege of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, China.
Jian-Xue YangDepartment of Pharmacy, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Based on the modification of the structure of dolutegravir, we introduced 1,2,3-triazole moieties with different substituted groups and obtained a lot of novel dolutegravir derivatives. The activity of A549 cells treated with the derivatives was examined, and most compounds showed good inhibitory effects. Among them, compounds

Indexed as

1,2,3-triazoleantitumorautophagyDNA damagedolutegravir

Identifiers

PMID37608893
PMCPMC10440426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.